[1]章屹峰 张倩倩 江洪.肠道微生物代谢产物短链脂肪酸与心血管疾病的研究进展[J].心血管病学进展,2019,(8):1165-1168.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.024]
 ZHANG Yifeng,ZHANG Qianqian,JIANG Hong.Gut Microbiota Metabolite Short-chain Fatty Acids and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(8):1165-1168.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.024]
点击复制

肠道微生物代谢产物短链脂肪酸与心血管疾病的研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年8期
页码:
1165-1168
栏目:
综述
出版日期:
2019-11-25

文章信息/Info

Title:
Gut Microbiota Metabolite Short-chain Fatty Acids and Cardiovascular Diseases
作者:
章屹峰 张倩倩 江洪
(武汉大学人民医院心内科 武汉大学心血管病研究所 心血管病湖北省重点实验室,湖北 武汉430060)
Author(s):
ZHANG Yifeng ZHANG Qianqian JIANG Hong
(Department of Cardiology, Renmin Hospital of Wuhan University; Cardiovascular Research Institute,Wuhan University; Hubei Key Laboratory of Cardiology, Wuhan 430060, Hubei, China)
关键词:
肠道微生物短链脂肪酸心血管疾病
Keywords:
Gut microbiotaShort-chain fatty acidsCardiovascular disease
DOI:
10.16806/j.cnki.issn.1004-3934.2019.08.024
摘要:
大量研究表明,肠道微生物代谢产物短链脂肪酸在高血压、动脉粥样硬化、心力衰竭等多种心血管疾病的发生与发展中起重要作用。同时,干预短链脂肪酸的产生量可明显改善心血管疾病的预后。现就短链脂肪酸与心血管疾病的研究进展进行综述。
Abstract:
Studies have shown that gut microbiota metabolites short-chain fatty acids(SCFAs) plays a significant role in the occurrence and development of cardiovascular diseases,such as hypertension,atherosclerosis and heart failure. Moreover,intervening intestinal SCFAs production has been proved to improve the prognosis of cardiovascular diseases. This article summarized recent research progress on the relationship of SCFAs and cardiovascular diseases.

参考文献/References:


[1] 胡盛寿,高润霖,刘力生,等. 《中国心血管病报告2018》概要[J]. 中国循环杂志 ,2019,34(3):209-220.

[2] Tang WHW,Li DY,Hazen SL. Dietary metabolism,the gut microbiome,and heart failure[J]. Nat Rev Cardiol,2019,16(3):137-154.

[3] Pluznick JL. Microbial short-chain fatty acids and blood pressure regulation[J]. Curr Hypertens Rep,2017,19(4):25.

[4] Tazoe H,Otomo Y,Kaji I,et al. Roles of short-chain fatty acids receptors,GPR41 and GPR43 on colonic functions[J]. J Physiol Pharmacol,2008,59 Suppl 2:251-262.

[5] Hu J,Lin S,Zheng B,et al. Short-chain fatty acids in control of energy metabolism[J]. Crit Rev Food Sci Nutr,2018,58(8):1243-1249.

[6] Bolognini D,Tobin AB,Milligan G,et al. The pharmacology and function of receptors for short-chain fatty acids[J]. Mol Pharmacol,2016,89(3):388-398.

[7] Yang T,Santisteban MM,Rodriguez V,et al. Gut dysbiosis is linked to hypertension[J]. Hypertension,2015,65(6):1331-1340.

[8] Li J,Zhao F,Wang Y,et al. Gut microbiota dysbiosis contributes to the development of hypertension[J]. Microbiome,2017,5(1):14.

[9] Qi Y,Aranda JM,Rodriguez V,et al. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension—A case report[J]. Int J Cardiol,2015,201:157-158.

[10] Pluznick JL. Renal and cardiovascular sensory receptors and blood pressure regulation[J]. Am J Physiol Renal Physiol,2013,305(4):F439-F444.

[11] Marques FZ,Nelson E,Chu PY,et al. High-fiber fiet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice[J]. Circulation,2017,135(10):964-977.

[12] Pluznick JL,Protzko RJ,Gevorgyan H,et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation[J]. Proc Natl Acad Sci U S A,2013,110(11):4410-4415.

[13] Wu MY,Li CJ. New insights into the role of inflammation in the pathogenesis of atherosclerosis[J]. Int J Mol Sci, 2017,18(10),pii: E2034.

[14] Jonsson AL,Backhed F. Role of gut microbiota in atherosclerosis[J]. Nat Rev Cardiol,2017,14(2):79-87.

[15] Li DY,Tang W. Gut microbiota and atherosclerosis[J]. Curr Atheroscler Rep,2017,19(10):39.

[16] Kasahara K,Krautkramer KA,Org E,et al. Interactions between roseburia intestinalis and diet modulate atherogenesis in a murine model[J]. Nat Microbiol,2018,3(12):1461-1471.

[17] Kitai T,Tang WHW. Gut microbiota in cardiovascular disease and heart failure[J]. Clin Sci (Lond),2018,132(1):85-91.

[18] Nagatomo Y,Tang WH. Intersections between microbiome and heart failure:revisiting the gut hypothesis[J]. J Card Fail,2015,21(12):973-980.

[19] Jakobsson HE,Rodriguez-Pineiro AM,Schutte A,et al. The composition of the gut microbiota shapes the colon mucus barrier[J]. EMBO Rep,2015,16(2):164-177.

[20] Hur KY,Lee MS. Gut microbiota and metabolic disorders[J]. Diabetes Metab J,2015,39(3):198-203.

[21] Ortega FB,Lavie CJ,Blair SN. Obesity and cardiovascular disease[J]. Circ Res,2016,118(11):1752-1770.

[22] Kachur S,Lavie CJ,de Schutter A,et al. Obesity and cardiovascular diseases[J]. Minerva Med,2017,108(3):212-228.

[23] Schwiertz A,Taras D,Schafer K,et al. Microbiota and SCFA in lean and overweight healthy subjects[J]. Obesity (Silver Spring),2010,18(1):190-195.

[24] Chambers ES,Viardot A,Psichas A,et al. Effects of targeted delivery of propionate to the human colon on appetite regulation ,body weight maintenance and adiposity in overweight adults[J]. Gut,2015,64(11):1744-1754.

[25] Tan J,McKenzie C,Potamitis M,et al. The role of short-chain fatty acids in health and disease[J]. Adv Immunol,2014,121:91-119.

[26] Pirlich M,Schutz T,Kemps M,et al. Prevalence of malnutrition in hospitalized medical patients:impact of underlying disease[J]. Dig Dis,2003,21(3):245-251.

[27] Venter CS,Vorster HH,Cummings JH. Effects of dietary propionate on carbohydrate and lipid metabolism in healthy volunteers[J]. Am J Gastroenterol,1990,85(5):549-553.

[28] Reynolds A,Mann J,Cummings J,et al. Carbohydrate quality and human health:a series of systematic reviews and meta-analyses[J]. Lancet,2019,393(10170):434-445.

[29] LeBlanc JG,Chain F,Martin R,et al. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria[J]. Microb Cell Fact,2017,16(1):79.

[30] Smits LP,Bouter KE,de Vos WM,et al. Therapeutic potential of fecal microbiota transplantation[J]. Gastroenterology,2013,145(5):946-953.

[31] Seekatz AM,Theriot CM,Rao K,et al. Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection[J]. Anaerobe,2018,53:64-73.

[32] Pouteau E,Nguyen P,Ballevre O,et al. Production rates and metabolism of short-chain fatty acids in the colon and whole body using stable isotopes[J]. Proc Nutr Soc,2003,62(1):87-93.

相似文献/References:

[1]蒋振江 刘富强 王军奎.肠道菌群与肥胖的关系研究进展[J].心血管病学进展,2023,(3):265.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.017]
 JIANG Zhenjiang,LIU Fuqiang,WANG Junkui.The Relationship Between Gut Microbiota and Obesity[J].Advances in Cardiovascular Diseases,2023,(8):265.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.017]
[2]王禹捷 吴璨 武楷文 孙晓滨.基于孟德尔随机化探索肠道菌群和血液代谢物与高血压及其并发症之间的因果关系[J].心血管病学进展,2024,(11):1039.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.017]
 WANG Yujie,WU Can,WU Kaiwen,et al.Exploring the Causal Relationship Between Gut Microbiota and Blood Metaboliteson on Hypertension and Hypertension- Related Complications Based on Mendelian Randomization[J].Advances in Cardiovascular Diseases,2024,(8):1039.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.017]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(81530011和81770364)
更新日期/Last Update: 2020-03-02